Comparative tolerability profiles of oral antidiabetic agents.
about
Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic DrugsOral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus.Review of management of type 2 diabetes mellitus.Metformin and lactic acidosis in diabetic humans.Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review.Insulin resistance and beta-cell dysfunction as therapeutic targets in type 2 diabetes.Treating type 2 diabetes--today's targets, tomorrow's goals.Metformin as a cause of late-onset chronic diarrhea.Cytoprotective Effects of Hydrophilic and Lipophilic Extracts of Pistacia vera against Oxidative Versus Carbonyl Stress in Rat Hepatocytes.Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv miceSex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin.Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes.Comparative safety of newer oral antidiabetic drugs.The prevalence of potential alcohol-drug interactions in older adults.The importance of treating cardiometabolic risk factors in patients with type 2 diabetes.Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation studyInsulin resistance and the long-term consequences of polycystic ovary syndrome.Prediction and validation of enzyme and transporter off-targets for metformin.Trends in the prescribing of oral agents for the management of type 2 diabetes mellitus in the United States, 1990-2001: does type of insurance influence access to innovation?Acarbose: its role in the treatment of diabetes mellitus.Insulin resistance.Comparative molecular field analysis of benzothiazepine derivatives: mitochondrial sodium calcium exchange inhibitors as antidiabetic agents.Metformin allergy.Inappropriate medication prescribing in residential care/assisted living facilities.Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin.Moderate alcohol consumption and adverse drug reactions among older adults.Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.Rosiglitazone: trials, tribulations and termination.Optimised extraction of β-carotene from Spirulina platensis and hypoglycaemic effect in streptozotocin-induced diabetic mice.Mechanisms of Action of Indigenous Antidiabetic Plants from the Boreal Forest of Northeastern Canada
P2860
Q26750845-7A5FF0DF-09AE-4F7E-A3CC-1401514482E8Q31795272-46422F11-EFA7-4EDF-9CBB-6AAAA99461B1Q33536960-09133103-71FE-49B6-8C2E-9BD0940620FEQ34163371-D3AEDD1A-CDDC-4134-812D-C37AD165651EQ34163377-F142D318-DE6B-4F78-9D00-DA20C099D185Q34168385-E40EFF77-0114-4AB7-9046-A785A95CF886Q34344990-4FAFEF2A-9D3B-4532-BF20-215DEA5DBF75Q34422790-9092B5D6-DEDB-42DD-9640-427EDBBD2CC3Q34443375-287DE704-3796-49D1-9BBD-01C0B114E176Q34515946-7124C065-BC6C-40F8-BEA6-8FFD7CF9DA2FQ34554315-B7F20C43-0F23-4064-AD28-0E5915304DDAQ35157635-9BDA8239-56C8-4F7A-BDD9-32C70D6E58C1Q35183780-49E5C7FA-6E8B-4655-BB0C-AB589487A2F6Q36624990-254C1916-0F11-47AB-BCE6-FDF408EFE9BCQ36850659-384232BD-59D6-4B1B-A27B-290C6C65A1E8Q37132923-6BE6B36F-3220-45E2-8E9C-6F0F891AC518Q37427914-6AD56FC4-D115-4527-BD30-29B892418FDDQ37696913-E547DDFE-4DDC-4AA1-8D36-33A3058CD98BQ37833622-50C6FD84-DE75-4F35-9DCC-BE958843B038Q38838317-C9EBD7EC-06A6-495F-9739-2334D387FD51Q40270389-F0683ED9-7DA3-40CB-A7B6-C7C416D9D40DQ41206503-0E1D59E0-6370-402E-99B5-BA1AE39D434BQ41258320-354CDFB2-6115-4CCB-BACF-50C5DEAE1056Q42108097-E18D8D4C-3BC6-44BD-BAC4-71A6708F2C00Q42721187-B22ABAC6-74BA-4F50-9293-930FD860060CQ44057625-F22037AC-D09E-4D1C-A438-BEB85B2A13E0Q44082233-939D02D9-D46B-4723-884D-16CC4FED32EFQ44150157-2DB11B81-906A-426C-B440-B06BE9D54E63Q44405600-CE7E6642-7F75-46BA-9259-93B06DA3D5E6Q53052728-42487EB2-17E0-4F3E-8B97-FF89FC8A24B2Q53218775-6F0BBBDE-3EBD-4BF2-BE1D-EC1E359EA03AQ59043922-EC76E566-358F-4668-AC39-5749CB112FD9
P2860
Comparative tolerability profiles of oral antidiabetic agents.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Comparative tolerability profiles of oral antidiabetic agents.
@en
type
label
Comparative tolerability profiles of oral antidiabetic agents.
@en
prefLabel
Comparative tolerability profiles of oral antidiabetic agents.
@en
P1433
P1476
Comparative tolerability profiles of oral antidiabetic agents.
@en
P2093
A J Krentz
C J Bailey
P304
P356
10.2165/00002018-199411040-00002
P50
P577
1994-10-01T00:00:00Z
P6179
1026564315